Telomerase inhibitors: a patent review (2010–2015)

References

• Ferlay J, Steliarova FE, Lortet TJ, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Boutayeb A, Boutayeb S. The burden of non-communicable diseases in developing countries. Int J Equity Health. 2005;4:1–8.
   PubMedGoogle Scholar
• Siegel R, Naishadham D. Cancer statistics, 2012. CA-Cancer J Clin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D. Cancer statistics, 2013. CA-Cancer J Clin. 2013;63:1–30.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA-Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003;94:15–21.
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–297.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272.
   PubMed Web of Science ®Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709–3714.
   PubMed Web of Science ®Google Scholar
• Patel P, Chaganti R, Motzer R. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614–619.
   PubMed Web of Science ®Google Scholar
• Green MR. Targeting targeted therapy. N Engl J Med. 2004;350:2191–2193.
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72–76.
   PubMed Web of Science ®Google Scholar
• Harley CB, Vaziri H, Counter CM, et al. The telomere hypothesis of cellular aging. Exp Gerontol. 1992;27:375–382.
   PubMed Web of Science ®Google Scholar
• Hayflick L. The illusion of cell immortality. Br J Cancer. 2000;83:841–846.
   PubMed Web of Science ®Google Scholar
• Shay J, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–791.
   PubMed Web of Science ®Google Scholar
• Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9–18.
   PubMed Web of Science ®Google Scholar
• Greider CW. Telomeres, telomerase and senescence. Bioessays. 1990;12:363–369.
   PubMed Web of Science ®Google Scholar
• Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG) n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 1988;85:6622–6626.
   PubMed Web of Science ®Google Scholar
• Biffi G, Tannahill D, Mc Cafferty J, et al. Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem. 2013;5:182–186.
   PubMed Web of Science ®Google Scholar
• Stansel RM, De LT, Griffith JD. T-loop assembly in vitro involves binding of TRF2 near the 3’-telomeric overhang. Embo J. 2001;20:5532–5540.
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015.
   PubMed Web of Science ®Google Scholar
• Counter CM, Avilion AA, Lefeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. Embo J. 1992;11:1921–1929.
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8:167–179.
   PubMed Web of Science ®Google Scholar
• Harley CB, Kim N, Prowse K, et al. Telomerase, cell immortality, and cancer. Symp Quant Biol. 1994;59:307–315.
   PubMedGoogle Scholar
• Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005;579:859–862.
   PubMed Web of Science ®Google Scholar
• Cunningham AP, Love WK, Zhang RW, et al. Telomerase inhibition in cancer therapeutics: molecular-based approaches. Curr Med Chem. 2006;13:2875–2888.
   PubMed Web of Science ®Google Scholar
• Feng J, Funk W, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269:1236–1241.
   PubMed Web of Science ®Google Scholar
• Henderson. 1995. EP666313A2.
   Google Scholar
• Bryant V, Junli F, Walter F. 1996. USA US5583016
   Google Scholar
• Geron Corporation; USA. 2014. WO2014085632A1; US8877723B2.
   Google Scholar
• Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955–959.
   PubMed Web of Science ®Google Scholar
• Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785–795.
   PubMed Web of Science ®Google Scholar
• Harrington L, Zhou W, McPhail T, et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 1997;11:3109–3115.
   PubMed Web of Science ®Google Scholar
• Kilian A, Bowtell DD, Abud HE, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet. 1997;6:2011–2019.
   PubMed Web of Science ®Google Scholar
• Geron Corporation, USA. 2012. US 8236774.
   Google Scholar
• Lingner J, Hughes TR, Shevchenko A, et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science. 1997;276:561–567.
   PubMed Web of Science ®Google Scholar
• Gomes NM, Ryder OA, Houck ML, et al. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell. 2011;10:761–768.
   PubMed Web of Science ®Google Scholar
• O’Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol. 2010;11:171–181.
   PubMed Web of Science ®Google Scholar
• Longhese MP, Bonetti D, Manfrini N, et al. Mechanisms and regulation of DNA end resection. Embo J. 2010;29:2864–2874.
   PubMed Web of Science ®Google Scholar
• Shore D, Bianchi A. Telomere length regulation: coupling DNA end processing to feedback regulation of telomerase. Embo J. 2009;28:2309–2322.
   PubMed Web of Science ®Google Scholar
• Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007;447:924–931.
   PubMed Web of Science ®Google Scholar
• Soder AI, Going JJ, Kaye SB, et al. Tumor specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene. 1998;16:979–983.
   PubMed Web of Science ®Google Scholar
• Hiyam E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;88:116–122.
   PubMedGoogle Scholar
• Murnane JP. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010;70:4255–4259.
   PubMed Web of Science ®Google Scholar
• Lansdorp PM, Verwoerd NP, Van De Rijke FM, et al. Heterogeneity in telomere length of human chromosomes. Hum Mol Genet. 1996;5:685–691.
   PubMed Web of Science ®Google Scholar
• Clark GM, Osborne CK, Levitt D, et al. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874–1881.
   PubMed Web of Science ®Google Scholar
• Donate LE, Blasco MA. Telomeres in cancer and ageing. Biol Sci. 2011;366:76–84.
   Web of Science ®Google Scholar
• Park KD, Seong SK, Park YM, et al. Telomerase reverse transcriptase related with telomerase activity regulates tumorigenic potential of mouse embryonic stem cells. Stem Cells Dev. 2011;20:149–157.
   PubMed Web of Science ®Google Scholar
• Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer. 1997;33:781–786.
   PubMed Web of Science ®Google Scholar
• Faraoni I, Turriziani M, Masci G, et al. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res. 1997;3:579–585.
   PubMed Web of Science ®Google Scholar
• Kondo S, Kondo Y, Li G, et al. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene. 1998;16:3323–3330.
   PubMed Web of Science ®Google Scholar
• Sun D, Lopez-Guajardo CC, Quada J, et al. Regulation of catalytic activity and processivity of human telomerase. Biochemistry. 1999;38:4037–4044.
   PubMed Web of Science ®Google Scholar
• Shin-ya K, Wierzba K, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc. 2001;123:1262–1263.
   PubMed Web of Science ®Google Scholar
• Puri N, Girard J. Novel therapeutics targeting telomerase and telomeres. J Cancer Sci Ther. 2013;5:127–130.
   Google Scholar
• El-Daly H, Kul M, Zimmermann S, et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005;105:1742–1749.
   PubMed Web of Science ®Google Scholar
• Gocha AR, Samir A, Joanna G, et al. WRN loss induces switching of telomerase-independent mechanisms of telomere elongation. Plos One. 2014;9(4):e93991–e93991.
   PubMed Web of Science ®Google Scholar
• Queisser A, Heeg S, Thaler M, et al. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis. Cancer Genetics. 2013;206(11):374–386.
   PubMed Web of Science ®Google Scholar
• Bechte OE, Dlaska M. Homologous recombination between telomeres is present in ALT and telomerase-positive immortal cells. Cancer Res. 2011;71(8):2993–2998.
   Google Scholar
• Wu G, Jiang X, Lee WH, et al. Assembly of functional ALT associated promyelocytic leukemia bodies requires Niimegen breakage syndrome Ι. Cancer Res. 2003;63:2589–2595.
   PubMed Web of Science ®Google Scholar
• Hu J, Hwang SS, Liesa M, et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell. 2012;148:651–663.
   PubMed Web of Science ®Google Scholar
• Ransburgh DJ, Chiba N, Ishioka C, et al. Identification of breast cancer mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res. 2010;70:988–995.
   PubMed Web of Science ®Google Scholar
• Li B, Reddy S, Comai L. Depletion of Ku70/80 reduces the levels of extrachromosomal telomeric circles and inhibits proliferation of ALT cells. Aging. 2011;3:395–406.
   PubMedGoogle Scholar
• Parkinson EK, Minty F. Anticancer therapy targeting telomeres and telomerase: current status. Bio Drugs. 2007;21:375–385.
   Google Scholar
• Tarkanyi I, Aradi J. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Biochimie. 2008;90:156–172.
   PubMed Web of Science ®Google Scholar
• Naasani I, Seimiya H, Yamori T, et al. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with compare analysis. Cancer Res. 1999;59(16):4004–4011.
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Colgin L, Yaguchi T, et al. Rhodacyanine dye MKT077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo. Caner Res. 2002;62(15):4434–4438.
   PubMed Web of Science ®Google Scholar
• Mueller S, Hartmann U, Mayer F, et al. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs. 2007;25(6):519–524.
   PubMed Web of Science ®Google Scholar
• Eldaly H, Martens UM. Telomerase inhibition and telomere targeting in hematopoietic cancer all lines with small non-nucleosidic synthetic compounds (BIBR1532). Methods Mol Biol. 2007;405:47–60.
   PubMedGoogle Scholar
• Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005;68:779–786.
   PubMed Web of Science ®Google Scholar
• Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer. 2008;98:677–683.
   PubMed Web of Science ®Google Scholar
• De CA, Lacroix L, Douarre C, et al. Targeting telomeres and telomerase. Biochimie. 2008;90:131–155.
   PubMed Web of Science ®Google Scholar
• Hochreiter AE, Xiao H, Goldblatt EM, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth and metastasis of breast cancer. Clin Cancer Res. 2006;12:3184–3192.
   PubMed Web of Science ®Google Scholar
• Ma D-L, Che C-M, Yan S-C. Platinum (II) complexes with dipyridophenazine ligands as human telomerase inhibitors and luminescent probes for G-quadruplex DNA. J Am Chem Soc. 2009;131:1838–1846.
   Google Scholar
• Tergaonkar Vinay; Singapore. 2014. WO2014051519A1.
   Google Scholar
• Snow BE, Erdmann N, Cruickshank J, et al. Functional conservation of the telomerase protein Est1p in humans. Curr Biol. 2003;13:698–704.
   PubMed Web of Science ®Google Scholar
• Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005;65:7866–7873.
   PubMed Web of Science ®Google Scholar
• Wang H-B, Wu S, Chu X, et al. A sensitive fluorescence strategy for telomerase detection in cancer cells based on T7 exonuclease-assisted target recycling amplification. Chem Commun. 2012;48(47):5916–5918.
   PubMed Web of Science ®Google Scholar
• Sharon E, Golub E, Niazov-Elkan A, et al. Analysis of telomerase by the telomeric hemin/G-quadruplex-controlled aggregation of au nanoparticles in the presence of cysteine. Anal Chem. 2014;86(6):3153–3158.
   PubMed Web of Science ®Google Scholar
• Pagano B, Cosconati S, Gabelica V, et al. State-of-the-art methodologies for the discovery and characterization of DNA G-quadruplex binders. Curr Pharm Des. 2012;18(14):1880–1899.
   PubMed Web of Science ®Google Scholar
• Agron LA, Beloglazkina EK. Vorozhcov NI.RU. 2011. WO2011126409.
   Google Scholar
• Sun Yat-Sen University; CHN. 2013. CN102898A; WO2014023063.
   Google Scholar
• Shanxi University; CHN. 2012. CN103044420A.
   Google Scholar
• Mokbel K. The evolving role of telomerase inhibitors in the treatment of cancer. Curr Med Res Opin. 2003;19:470–472.
   PubMed Web of Science ®Google Scholar
• Zvereva MI, Zatsepin TS, Azhibek DM, et al. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics. Biochemistry (Moscow). 2015;80(3):251–259.
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257–265.
   PubMed Web of Science ®Google Scholar